Anti-cytokine therapeutics: History and update

Current Pharmaceutical Design

Volumn 15, Issue 17, 2009, Pages 1998-2025

  Ratsimandresy, Rojo A ^a   Rappaport, Jay ^b   Zagury, Jean François ^a  

^a Bioinformatique et Chimie Moléculaire   (France)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Anti cytokine therapy; Asthma; Autoimmunity; Cancer; Cytokines; Diabetes; Immune mediated inflammatory disease; Inflammatory bowel disease; Multiple sclerosis; Psoriasis; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ATACICEPT; BELIMUMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; DNA VACCINE; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; PEPTIDE VACCINE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STELARA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VASCULOTROPIN;

ADJUVANT THERAPY; ALLERGIC ENCEPHALOMYELITIS; ANKYLOSING SPONDYLITIS; ARTHRITIS; ASTHMA; AUTOIMMUNE DISEASE; BREAST CANCER; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATORY INFILTRATE; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TH2 CELL; ULCERATIVE COLITIS; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; IMMUNIZATION; RECEPTORS, CYTOKINE; VACCINES;

EID: 68449085755     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788453130     Document Type: Review

References (331)

1. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999; 162: 1246-51.
2. Cohen S, Levi-Montalcini R, Hamburger V. A nerve growthstimulating factor isolated from sarcomas 37 and 180. PNAS 1954; 40: 1014-8.
3. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-67.
4. Wheelock EF. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965; 149: 310-1.
5. David JR. Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. PNAS 1966; 56: 72-7.
6. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966; 153: 80-2.
7. Carswell EA, Old LJ, Kassel RL, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. PNAS 1975; 72: 3666-70.
8. Morgan DA, Ruscetti FW, Gallo RC. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007-8
9. Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem 2002; 277: 29355-8.
10. Mosmann TR. Two types of murine helper T cell clone. J Immunol 1986; 136: 2348-57.
11. Jasin HE, Dingle JT. Human mononuclear cell factors mediate cartilage matrix degradation through chondrocyte activation. J Clin Invest 1981; 68: 571-81.
12. McGuire-Goldring MB, Meats JE, Wood DD, Ihrie EJ, Ebsworth NM, Russell RG. In vitro activation of human chondrocytes and synoviocytes by a human interleukin-1-like factor. Arthritis Rheum 1984; 27: 654-62
13. Mizel SB, Dayer J-M, Krane SM, Mergenhagen SE. Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). PNAS 1981; 78: 2474-7.
14. Fontana A, Hengartner H, Weber E, Fehr K, Grob P, Cohen G. Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 1982; 2: 49-53.
15. Nouri AME, Panayi GS, Goodman SM. Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol 1984; 55: 295-302.
16. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322: 547-9.
17. Husby G, Williams RJ. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988; 1: 363-71.
18. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni CE, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521-8.
19. McInnes IB, Al-Mughales J, Field M, Leung BP, Huang F-P, Dixon R, et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996; 2: 175-82.
20. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997; 3: 189-95.
21. McInnes IB, Liew FY. Interleukin 15: A proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 1998; 19: 75-9.
22. Rückert R, Brandt K, Ernst M, Marienfeld K, Metzler C, Budagian V, et al. Interleukin-15 stimulated macrophages to activate CD4+ T cells: A role in the pathogenesis of rheumatoid arthritis? Immunology 2009; 126: 63-73.
23. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988; 18: 1797-801.
24. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784-8.
25. Nawata Y, Eugui EM, Lee SW, A llison AC. IL-6 is the principal factor produced by synovia of patients with rheumatoid arthritis that induces B-lymphocytes to secrete immunoglobulins. Ann N Y Acad Sci 1989; 557: 230-8.
26. Bettelli E, Carrier Y, Gao W, Korn TS, T.B, Oukka M, Weiner HL, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441: 235-8.
27. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441: 231-4.
28. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis and Rheumatism 2005; 52: 818- 25.
29. Kimura A, Naka T, Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. PNAS 2007; 104: 12099-104.
30. Germann TS, Jacek, Hess H, Störkel S, Podlaski FJ, Gately MK, Schmitt E, et al. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. PNAS 1995; 92: 4823-7.
31. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan TK, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951-7
32. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345-52.
33. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJJK, Jay K, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kB Ligand/Osteoprotegerin balance. J Immunol 2003; 170: 2655-62.
34. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. PNAS 2003; 100: 5986-90.
35. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-32.
36. Romagnani S. Human Th17 cells. Arthritis Res Ther 2008; 10: Epub.
37. Hodgson HJF. In: Allan RN, Jonathan MR, Hanauer SB Ed, Inflamm Bowel Dis. New York, Churchill Livingstone. 1997, 343-7.
38. Tanner AR, Arthur MJ, Wright R. Macrophage activation, chronic inflammation and gastrointestinal disease. Gut 1984; 25: 760-83.
39. Miura M, Hiwatashi N. Cytokine production in inflammatory bowel disease. J Clin Lab Immunol 1985; 18: 81-6.
40. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn's disease. Gut 1989; 30: 835-8.
41. Nakamura M, Saito H, Kasanuki J, Tamura Y, Yoshida S. Cytokine production in patients with inflammatory bowel disease. Gut 1992; 33: 933-7.
42. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut 1990; 31: 686-9.
43. Mitsuyama K, Sasaki E, Toyonaga A, Ikeda H, Tsuruta O, Irie A, et al. Colonic mucosa interleukin-6 in inflammatory bowel disease. Digestion 1991; 50: 104-11.
44. Stevens C, Walz G, Singaram C, Lipman ML, Zanker BM, A, Antonioli D, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37: 818-26.
45. Reinecker H-C, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
46. Maeda M, Watanabe N, Neda H, Yamauchi N, Okamoto T, Sasaki H, et al. Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol Immunotoxicol 1992; 14: 451-61.
47. Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, F. DW. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1992; 102: 529-37.
48. Casini-Raggi VK, L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154: 2434-40.
49. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer Zum Büschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448-55.
50. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999; 117: 1078-88.
51. Wiekowski MT, Leach MW, Evans EW, Sullivan L, Chen SC, Vassileva G, et al. Ubiquituous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol 2001; 166: 7563-70.
52. Krajina T, Leithäuser F, Möller P, Trobonjaca Z, Reimann J. Colonic lamina propria dendritic cells in mice with CD4+ T cell-induced colitis. Eur J Immunol 2003; 33: 1073-83.
53. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan TK, McKenzie B, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-6.
54. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
55. Fontana A, Fierz W, Wekerle H. Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature 1984; 307: 273-6.
56. Kennedy MK, Torrance DS, Picha KS, Mohler KM. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992; 149: 2496-505.
57. Bauer J, Berkenbosch F, Van Dam A, Dijkstra C. Demonstration of interleukin-1 beta in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultra-structural level. J Neuroimmunol 1993; 48: 13-21.
58. Stroemer RP, Rothwell NJ. Cortical protection by localized striatal injection of IL-1RA following cerebral ischemia in the rat. J Cereb Blood Flow Metab 1997; 17: 597-604.
59. Spohn G, Guler R, Johansen P, Keller I, Jacobs M, Beck M, et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 2007; 178: 7450-7.
60. Hofman FM, Hinton DR, Johnson KP, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170: 607-12
61. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37: 424-35.
62. Kuroda Y, Shimamoto Y. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuro-immunol 1991; 34: 159-64.
63. Issazadeh S, Ljungdahl A, Höjeberg B, Mustafa M, Olsson T. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: Dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. J Neuro-immunol 1995; 61: 205-12.
64. Liu J, Marino MWW, Grace, Grail D, Dunn A, Bettadapura J, Slavin AJ, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4: 78-83.
65. Selmaj K, Raine CS. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 1995; 45: S44-9.
66. Panitch H, Hirsch R, Schindler J, Johnson K. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097-102.
67. Renno T, Lin JY, Piccirillo C, Antel J, Owens T. Cytokine production by cells in cerebrospinal fluid during experimental allergic encephalomyelitis in SL/J mice. J Neuroimmunol 1994; 49: 1-7.
68. Renno T, Taupin V, Bourbonnière L, Verge G, Tran EH, De Simone R, et al. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci 1998; 12: 376-89.
69. Petereit HF, Nolden S, Schoppe S, Bamborschke S, Pukrop R, Heiss WD. Low interferon gamma producers are better treatment responders: A two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 2002; 8: 492-4.
70. Krakowski M, Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996; 26: 1641-6.
71. Tran EH, Prince EN, Owens T. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J Immunol 2000; 164: 2759-69.
72. Duong TT, Finkelman FD, Singh BS, G. H. Effect of anti-interferon-gamma monoclonal antibody treatment on the development of experimental allergic encephalomyelitis in resistant mouse strains. J Neuroimmunol 1994; 53: 101-7.
73. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996; 156: 5-7.
74. Smith T, Hewson AK, Kingsley CI, Leonard JP, Cuzner ML. Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol 1997; 150: 1909-17.
75. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995; 182: 1985-96.
76. Matusevicius D, Kivisäkk P, Navikas V, Söderström M, Fredrikson S, Link H. Interleukin-12 and perforin mRNA expression is augmented in blood mononuclear cells in multiple sclerosis. Scand J Immunol 1998; 47: 582-90.
77. Gran B, Zhang G-X, Yu S, Li J, Chen X-H, Ventura ES, et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: Evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002; 169: 7104-10.
78. Wang X, Chen M, Wandinger KP, Williams G, Dhib-Jalbut S. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: Relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol 2000; 165: 548-57.
79. Makhlouf K, Comabella M, Imitola J, Weiner HL, Khoury SJ. Oral salbutamol decrases in IL-12 in patients with secondary progressive multiple sclerosis. J Neuroimmunol 2001; 117: 156-65.
80. van Boxel-Dezaire AHH, Hoff SCJ, van Oosten BW, Verweij CL, Dräger AM, Adèr HJvH, J. C, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999; 45: 695-703.
81. Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002; 110: 493-7.
82. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-40.
83. Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5: 101-4.
84. Tzartos JS, Friese MAC, Matthew J, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172: 146-55.
85. Li J, Gran B, Zhang G-X, Ventura ES, Siglienti I, Rostami A, et al. Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. J Neurol Sci 2003; 215: 95-103.
86. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation in the brain. Nature 2003; 421: 744-8.
87. Nerup J, Lernmark A. Autoimmunity in insulin-dependent diabetes mellitus. Am J Med 1981; 70: 135-41.
88. Itoh N, Hanafusa T, Miyazaki A, Miyagawa J-I, Yamagata K, Yamamoto K, et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 1993; 92: 2313-22.
89. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986; 232: 1545-7.
90. Baquerizo HR, Alex. Interferon-gamma sensitizes rat pancreatic islet cells to lysis by cytokines and cytotoxic cells. J Autoimmun 1990; 3 Suppl 1: 123-30.
91. Mandrup-Poulsen T, Zumsteq U, Reimers J, Pociot F, Morch L, Helqvist S, et al. Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. Cytokine 1993; 5: 185-91.
92. Campbell IL, Kay TWH, Oxbrow L, Harrison LC. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 1991; 87: 739-42.
93. Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am J Pathol 1995; 147: 1193-9.
94. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC. Inducible nitric oxide synthase (iNOS) in pancreatic islets of nonobese diabetic mice: Identification of iNOS-expressing cells and relationships to cytokines expressed in the islets. Endocrinology 1996; 137: 2093-9.
95. von Herrath MG, Oldstone MBA. Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med 1997; 185: 531-9.
96. Chung Y-H, Jun H-S, Kang Y, Hirasawa K, Lee B-R, Van Rooijen N, et al. Role of macrophages and macrophages-derived cytokines in the pathogenesis of Kilham rat virus-induced autoimmune diabetes-resistant biobreeding rats. J Immunol 1997; 159: 466-71.
97. Suarez-Pinzon WL, Rajotte RV, Mosmann TR, Rabinovitch A. Both CD4+ and CD8+ T-cells in syngeneic islet grafts in NOD mice produce interferon-gamma during beta-cell destruction. Diabetes 1996; 45: 1350-7.
98. Charlton B, Lafferty KJ. The Th1/Th2 balance in autoimmunity. Curr Opin Immunol 1995; 7: 793-8.
99. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC, Power RF. IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J Immunol 1995; 154: 4874-82.
100. Hultgren B, Huang X, Dybdal N, Stewart T. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996; 45: 812-7.
101. Wogensen L, Lee M-S, Sarvetnick N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice. J Exp Med 1994; 179: 1379-84.
102. Trembleau S, Penna G, Gregori S, Giarratana N, Adorini L. IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12 induced IFN-gamma. J Immunol 2003; 170: 5491-501.
103. Netea MG, Hancu N, Blok WL, Grigorescu-Sido P, Popa L, Popa V, et al. Interleukin 1-beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: Comparison to long-standing diabetes and healthy individuals. Cytokine 1997; 9: 284-7.
104. Rapoport MJ, Vardi AM, Ramot Y, Winker R, Hindi A, Bistritzer T. Decreased secretion of Th2 cytokines precedes up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. J Autoimmun 1998; 11: 635-42.
105. Halminen M, Simell O, Knip M, Ilonen J. Cytokine expression in unstimulated PBMC of children with type 1 diabetes and subjects positive for diabetes-associated autoantibodies. Scand J Immunol 2001; 53: 510-3.
106. Sempé P, Rochard MFB, JF, Boitard C. Evidence of CD4+ regulatory T cells in the non-obese diabetic male mouse. Diabetologia 1994; 37: 337-43.
107. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109: 131-40.
108. Schön MP, Boehncke W-H. Psoriasis. N Engl J Med 2005; 352: 1899-912.
109. Paukkonen K, Naukkarinen A, Horsmanheimo M. The development of manifest psoriatic lesions is linked with the invasion of CD8+ T cells and CD11c + macrophages into the epidermis. Arch Dermatol Res 1992; 284: 375-9.
110. Takashima A, Morita A. Genomic, phenotypic, and functional analyses of T cells in patients with psoriasis undergoing systemic cyclosporin A treatment. J Invest Dermatol 1991; 96: 376-82.
111. Jegasothy BV, Ackerman CD, Todos S, Fung JJ, Abu-Elmagd KS, TE. Tacrolimus (FK 506) - a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992; 128: 781-5.
112. Asadullah K, Sterry W, Sephanek K, Jasulaitis D, Leupold M, Audring H, et al. IL-10 is a key cytokine in psoriasis. J Clin Invest 1998; 101: 783-94.
113. Diezel W, Waschke S, Sönnichsen N. Detection of interferon in the sera of patients with psoriasis, and its enhancement by PUVA treatment. Br J Dermatol 1983; 109: 549-52.
114. Bjerke J, Livden J, Degré M, Matre R. Interferon in suction blister fluid from psoriatic lesions. Br J Dermatol 1982; 108: 295-9.
115. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (Cytotoxic T Lymphocyte) and Th1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113: 752-9.
116. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243: 1464-6.
117. Barker JNWN, Sarma V, Mitra RS, Dixit VM, Nickoloff BJ. Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest 1990; 85: 605-8.
118. Nickoloff BJ, Karabin GD, Barker JNWN, Griffiths CEM, Sarma V, Mitra RS, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991; 138: 129-41.
119. Schröder J-M, Gregory H, Young J, Christophers E. Neutrophilactivating proteins in psoriasis. J Invest Dermatol 1992; 98: 241-7.
120. Teranishi Y, Mizutani H, Murata M, Shimizu M, Matsushima K. Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: Relation to focal infection and response to treatments. J Dermatol Sci 1995; 10: 8-15.
121. Okubo Y, Koga M. Peripheral blood monocytes in psoriatic patients overproduce cytokines. J Dermatol Sci 1998; 17: 223-32.
122. Jacob SE, Nassiri M, Kerdel FA, Vincek V. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 2003; 12: 309-13.
123. Vollmer S, Menssen AT, P, Schendel D, Prinz JC. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 1994; 24: 2377-82.
124. Mussi A, Bonifati C, Carducci M, Viola M, Tomaselli R, Sacerdoti G, et al. IL-10 levels are decreased in psoriatic lesional skin as compared to the psoriatic lesion-free and normal skin suction blister fluids. J Biol Regul Homeost Agents 1994; 8: 117-20.
125. Rubin JS, Osada H, Finch PW, Taylor WG, Rudikoff S, Aaronson SA. Purification and characterization of a newly identified growth factor specific for epithelial cells. PNAS 1989; 86: 802-6.
126. Finch PW, Murphy F, Cardinale IR, Krueger JG. Altered expression of keratinocyte growth factor and its receptor in psoriasis. Am J Pathol 1997; 151: 1619-28.
127. Miossec P, Yu C-L, Ziff M. Lymphocyte chemotactic activity of human interleukin 1. J Immunol 1984; 133: 2007-11.
128. Granstein RD, Margolis R, Mizel SB, Sauder DN. In vivo inflammatory activity of epidermal cell-derived thymocyte activating factor and recombinant interleukin 1 in the mouse. J Clin Invest 1986; 77: 1020-7.
129. Bell TV, Harley CB, Stetsko D, Sauder DN. Expression of mRNA homologous to interleukin 1 in human epidermal cells. J Invest Dermatol 1987; 88: 375-9.
130. Romero LI, Ikejima T, Pincus SH. In situ localization of interleukin-1 in normal and psoriatic skin. J Invest Dermatol 1989; 93: 518-22.
131. Gomi T, Shiohara T, Munakata T, Imanishi K, Nagashima M. Interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis. Arch Dermatol 1991; 127: 827-30.
132. Grossman RM, Krueger JG, Yourish D, Granelli-Piperno A, Murphy DP, May LT, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. PNAS 1989; 86: 6367-71.
133. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RDR. Elevated tumour necrosis factor alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-51.
134. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11: 115-8.
135. Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptative immunity. Annu Rev Immunol 1995; 13: 251-76.
136. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998; 111: 1053-7.
137. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-30.
138. Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-4.
139. Miljkovic D, Cvetkovic I, Vickovic O, Stosic-Grujicic S, Mostarica Stojkovic M, Trajkovic V. The role of interleukin-17 in inducible nitric oxide synthase-mediated nitric oxide production in endothelial cells. Cell Mol Life Sci 2003; 60: 518-25.
140. Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, et al. Interleukin-11 therapy selectively downregulates type 1 cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104: 1527-37.
141. Belladonna ML, Renauld J-C, Bianchi R, Vacca C, Fallarino F, Orabona C, et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol 2002; 168: 5448-54.
142. Kopp T, Lenz P, Bello-Fernandez C, Kastelein RA, Kupper TS, Stingl G. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: Evidence for enhanced cutaneous immunity. J Immunol 2003; 170: 5438-44.
143. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Ouyang W. Interleukin-22, a T(h)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51.
144. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003; 112: 1571-80.
145. Renauld J-C. New insights into the role of cytokines in asthma. J Clin Pathol 2001; 54: 577-89.
146. Cookson W. The alliance of genes and environment in asthma and allergy. Nature 1999; 402: B5-11.
147. Minshall EM, Leung DYM, Martin RJ, Song YL, Cameron L, Ernst P, et al. Eosinophil-associated TGF-beta 1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997; 17: 326-33.
148. Ohno I, Nitta Y, Yamauchi K, Hoshi HH, M, Woodley K, O'Byrne P, et al. Transforming growth factor beta 1 (TGF beta 1) gene expression by eosinophils in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1996; 15: 404-9.
149. Azzawi M, Bradley B, Jeffery PK, Frew AJ, Wardlaw AJ, Knowles G, et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990; 142: 1407-13.
150. Azzawi M, Johnston PW, Majumdar S, Kay AB, Jeffery PK. T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis 1992; 145: 1477-82.
151. Robinson DS, Hamid QA, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant Th2-like bronchoalveolar Tlymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298-304.
152. Gratziou C, Carroll M, Walls A, Howarth P, Holgate ST. Early changes in T lymphocytes recovered by bronchoalveolar lavage after local allergen challenge of asthmatic airways. Am Rev Respir Dis 1992; 145: 1259-64.
153. Bousquet J, Chanez P, Lacoste J, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033-9.
154. Gleich G. The eosinophil and bronchial asthma: Current understanding. J Allergy Clin Immunol 1990; 85: 422-36.
155. Djukanovic R, Roche W, Wilson J, Beasley C, Twentyman O, Howarth R, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434-57.
156. Parronchi P, Macchia D, Piccinni M-P, Biswas P, Simonelli C, Maggi E, et al. Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. PNAS 1991; 88: 4538-42.
157. Walker C, Kaegi MK, Braun P, Blaser K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease activity. J Allergy Clin Immunol 1991; 88: 935-42.
158. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JCJ. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992; 146: 109-15.
159. Del Prete G, De Carli M, D'Elios MM, Mastrelli P, Ricci M, Fabbri L, et al. Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur J Immunol 1993; 23: 1445-9.
160. Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE. Mast cell lines produce lymphokines in response to crosslinkage of Fc epsilon RI or to calcium ionophores. Nature 1989; 339: 64-7.
161. Bradding P, Roberts J, Britten K, Montefort S, Djukanovic R, Mueler R, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10: 471-80
162. Broide DH, Paine MM, Firestein GS. Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992; 90: 1414-24
163. Corry D, Folkesson H, Warnock M, Erle D, Matthay M, Wiener-Kronish J, et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996; 183: 109-17.
164. Hudak SA, Gollnick SO, Conrad DH, Kehry MR. Murine B-cell stimulatory factor 1 (interleukin 4) increases expression of the Fc receptor for IgE on mouse B cells. PNAS 1987; 84: 4606-10.
165. Lebman DA, Coffman RL. Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures. J Exp Med 1988; 168: 853-62
166. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994; 12: 635-73.
167. Kopf M, Le Gros G, Bachmann MF, Lamers MC, Bluethmann H, Köhler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362: 245-8.
168. Cohn L, Homer RJ, MacLeod H, Mohrs M, Brombacher F, Bottomly K. Th2-induced airway mucus production is dependent on IL-4R-alpha, but not on eosinophils. J Immunol 1999; 162: 6178- 83.
169. Rankin JA, Picarella DE, Geba GP, Temann UA, Prasad BD, B, Tarallo A, et al. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: Lymphocytic and eosinophilic inflammation without airway hyperreactivity. PNAS 1996; 93: 7821-5.
170. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988; 167: 219-24.
171. Venge P. Eosinophils and respiratory disease. Respir Med 2001; 95: 168-9.
172. Zurawski SM, Vega FJ, Huyghe B, Zurawski G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993; 12: 2663-70.
173. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008; 132: 179-81.
174. Kasaian MT, Miller DK. IL-13 as a therapeutic target for respiratory disease. Biochem Pharmacol 2008; 76: 147-55.
175. Huang S-K, Xiao H-Q, Kleine-Tebbe J, Paciotti G, Marsh DG, Lichtenstein LM, et al. IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 1995; 155: 2688-94.
176. Grünig G, Warnock ML, Wakil AE, Venkayya R, Brombacher F, Rennick DM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 2261-3.
177. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999; 17: 255-81.
178. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103: 779-88.
179. McKenzie GJ, Fallon PG, Emson CL, Grencis RK, McKenzie ANJ. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1999; 189: 1565-72.
180. Laitinen T, Kauppi P, Ignatius J, Ruotsalainen T, Daly MJ, Kääriäinen H, et al. Genetic control of serum IgE levels and asthma: Linkage and linkage disequilibrium studies in an isolated population. Hum Mol Genet 1997; 6: 2069-76.
181. Demoulin JR, JC. Interleukin 9 and its receptor: An overview of structure and function. Int Rev Immunol 1998; 16: 345-64.
182. Gounni AS, Nutku E, Koussih L, Aris F, Louahed J, Levitt RC, et al. IL-9 expression by human eosinophils: Regulation by IL-1beta and TNF-alpha. J Allergy Clin Immunol 2000; 106: 460-6.
183. Virchow JCJ, Walker C, Hafner D, Kortsik C, Werner P, Matthys H, et al. T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. Am J Respir Crit Care Med 1995; 151: 960-8.
184. Shimbara A, Christodoulopoulos P, Gounni AS, Olivenstein R, Nakamura Y, Levitt RC, et al. IL-9 and its receptor in allergic and nonallergic lung disease: Increased expression in asthma. J Allergy Clin Immunol 2000; 104: 108-15.
185. Howarth P, Babu K, Arshad H, Lau L, Buckley M, McConnel W, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-8
186. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986; 46: 5629-32.
187. Ferrara N, Houck K, Jakeman L, Winer J, Leung D. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47: 211-8.
188. Ferrara N, Houck K, Jakeman L, Leung D. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
189. Gerber H-P, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003; 81: 20-31.
190. Watanabe N, Niitsu Y, Sone H, Neda H, Urushizaki I, Yamamoto A, et al. Therapeutic effect of endogenous tumor necrosis factor on ascites Meth A sarcoma. Journal Immunopharmacol 1986; 8: 271-83.
191. Sohmura Y, Nakata K, Yoshida H, Kashimoto S, Matsui Y, Furuichi H. Recombinant human tumor necrosis factor - II. Antitumor effect on murine and human tumors transplanted in mice. Int J Immunopharmacol 1986; 8: 357-68.
192. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47: 2986-9.
193. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman J. A phase I trial of intravenously-administered recombinant necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6: 1328-34.
194. Malik ST, Griffin DB, Fiers W, Balkwill FR. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer 1989; 44: 918-25.
195. Malik ST, Naylor MS, East N, Oliff A, Balkwill FR. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 1990; 26: 1031-4.
196. Naylor MS, Malik ST, Stamp GW, Jobling T, Balkwill FR. In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer 1990; 26: 1027-30.
197. von Biberstein S, Spiro J, Lindquist R, Kreutzer D. Enhanced tumor cell expression of tumor necrosis factor receptors in head and neck squamous cell carcinoma. Am J Surg 1995; 170: 416-22.
198. Malik ST. Tumour necrosis factor: Roles in cancer pathophysiology. Semin Cancer Biol 1992; 3: 27-33.
199. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006; 25: 435-57.
200. Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS. Transforming growth factor-beta 1 overexpression produces lung resistance in vivo: reversal by decorin. In vivo 1997; 11: 463-73.
201. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
202. van der Laken CJ, Voskuyl AE, Roos JC, van Walsum MS, de Groot ER, Wolbink G, et al. Imaging and serum analysis of immune complex formation of radiolabelled Infliximab and anti-Infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007; 66: 253-6.
203. Tracey D, Klareskog L, Sasso EHS, Jochen G, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther 2008; 117: 244-79.
204. Choy EHS, Hazleman B, Smith M, Moss K, Lisi L, Scott DGI, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002; 41: 1133-7.
205. Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized anti-tumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: An exploratory study. Aliment Pharmacol Ther 2004; 20: 1337-46.
206. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with Certolizumab Pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50.
207. Keystone EC, Van der Heijde D, Mason D, Landewé R, Van Vollenhoven RF, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis and Rheumatism 2008; 58: 3319-29.
208. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab Pegol for the treatment of Crohn's disease. J Exp Med 2007; 357: 228-38.
209. Mease PJ, Keystone ECM, D, Smolen J, Schiff MH. Safety of Certolizumab Pegol with methotrexate in patients with active rheumatoid arthritis. EULAR. Paris, France. 2008; June 11-14
210. van Vollenhoven RF, Felson D, Weinblatt ME, Strand V, Mason D, Luitjens K, et al. ACR-Hybrid analysis confirms benefit of Certolizumab Pegol with methotrexate in patients with rheumatoid arthritis: Data from the RAPID 1 and 2 trials. EULAR. Paris, France. 2008; June 11-14
211. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled dose-ranging study. Arthritis Rheum 2008; 58: 964-75.
212. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. [THU-0138] Golimumab (GLM), a new human anti-TNF-alpha monoclonal antibody, administered subcutaneously (sc) every 4 weeks in methotrexate-naïve patients with active rheumatoid arthritis (RA): A randomized, double-blind, placebo-controlled, GO-BEFORE study. EULAR 2008. Paris, France. 2008; June 11-14
213. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab, a human antibody to TNF{alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: The GO-FORWARD Study. Ann Rheum Dis 2008: Epub ahead of print.
214. Smolen J, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): Results of the randomized, doubleblind, placebo-controlled trial. Ann Rheum Dis 2008; 67 (Suppl II): 50.
215. Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of Adalimumab, Etanercept and Infliximab for the treatment of rheumatoid arthritis in adults and an economical evaluation of their cost-effectiveness. Health Technol Assess 2006; 10: Iii-iv, xi-xiii, 1-229.
216. Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of Infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1017-24.
217. Kaplan GG, Hur C, Korzenick JR, Sands BE. Infliximab dose escalation vs. initiation of Adalimumab for loss of response in Crohn's disease: A cost-effectiveness analysis. Aliment Pharmacol Ther 2007; 26: 1509-20.
218. Lin J, Ziring D, Desai S, Kim S, Kim S, WOng M, et al. TNFalpha blockade in human diseases: An overview of efficacy and safety. Clin Immunol 2008; 126: 13-30.
219. Naguwa SM. Tumor necrosis factor inhibitor therapy for rheumatoid arthritis. Ann N Y Acad Sci 2005; 1051: 709-15.
220. Kristensen LEC, R, Bliddal H, Geborek P, Danneskiold-Samsoe BS, T. The number needed to treat for Adalimumab, Etanercept, and Infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: A systematic literature review. Scand J Rheumatol 2007; 36: 411-7.
221. Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: A meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007; 46: 1140-7.
222. Keystone EC, Haraoui BB, V. P. Role of Infliximab in the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: S200-2.
223. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with Infliximab in addition to methtrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after Infliximab withdrawal. Arthritis Rheum 2005; 52: 27-35.
224. Sizova L. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Brit J Clin Pharmacol 2008: Epub ahead of print.
225. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNFalpha blockade in human diseases: Mechanisms and future directions. Clin Immunol 2008; 126: 121-36.
226. Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of Etanercept are distinct from Infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc 2007; 12: 9-15.
227. Slifman NR, Gershon SK, Lee J-H, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48: 319-24.
228. Lee J-H, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists Infliximab and Etanercept. Arthritis Rheum 2002; 46: 2565-70.
229. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497-502.
230. Chakravarty EF, Genovese MC. Associations between rheumatoid arthritis and malignancy. Rheum Dis Clin North Am 2004; 30: 271-84.
231. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692-701.
232. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10: R45.
233. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
234. den Broeder AA, de Jong E, Franssen MJAM, Jeurissen MEC, Flendrie M, van den Hoogen FHJ. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006; 65: 760-62.
235. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester G, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 927-34.
236. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester G, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1006- 12.
237. Salliot C, Dougados M, Gossec L. Risk of serious infection during Rituximab, Abatacept and Anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 2008: Epub ahead of print.
238. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009.
239. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3.
240. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer J-L, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188: 1185-90.
241. Cancro MP. The BLyS/BAFF family of ligands and receptors: Key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006; 65: iii34-6.
242. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
243. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235-46.
244. McKay J, Chwalinska-Sadowska H, Boling E, Valente R, Limanni A, Racewicz A, et al. [OP-1920] Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogenous subject population. 69th Annual Meeting of the American College of Rheumatology. San Diego, Calif. 2005; Nov 16
245. No-authors-listed. Belimumab: Anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, Human monoclonal antibody to B-Lymphocyte stimulator. Drugs in R&D 2008; 9: 197-202.
246. Steinbrook R. The price of sight - Ranibizumab, Bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355: 1409-12.
247. Ignoffo RJ. Overview of Bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004; 61: S21-6.
248. Shih T, Lindley C. Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28: 1779-802.
249. Ellis LM, Hicklin DJ. VEGF-targeted therapy: Mechanisms of antitumour activity. Nat Rev Cancer 2008; 8: 579-91.
250. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on Bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007; 8: 15-27.
251. Sanborn RE, Sandler AB. The safety of Bevacizumab. Expert Opinion Drug Saf 2006; 5: 289-301.
252. Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology (Willinston Park) 2006; 20: 21-8.
253. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
254. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
255. Sandborn WJ. A randomized trial of ustekinumab, a human interleukin-12/ 23 monoclonal antibody, in patients with moderate-tosevere Crohn's disease. Gastroenterology 2008; 135: 1130-41.
256. Brasier AR, Victor S, Boetticher G, Ju H, Lee C, Bleecker ER, et al. Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. J Allergy Clin Immunol 2008; 121: 30-7.
257. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KFB, Elisabeth H. "Refractory" eosinophilic airway inflammation in severe asthma. Am J Respir Crit Care Med 2004; 170: 601-5.
258. Zagury D, Bernard J, Halbreich A, Bizzini B, Carelli C, Achour A, et al. One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: A new strategy. J Acquir Immune Defic Syndr Hum Retrovirol 1992; 5: 676-81.
259. Gringeri A, Santagostino E, Mannucci PM, Tradati F, Cultraro D, Buzzi A, et al. A randomized, placebo-controlled, blind anti-AIDS clinical trial: Safety and immunogenicity of a specific anti-IFN alpha immunization. J Acquir Immune Defic Syndr 1994; 7: 978-88.
260. Gringeri A, Santagostino E, Cusini M, Muça-Perja M, Marinoni A, Burny A, et al. Absence of clinical, virological, and immunological signs of progression in HIV-1 infected patients receiving active anti-interferon-[alpha] immunization: A 30-month follow-up report. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: 55-67.
261. Gringeri A, Musicco M, Hermans P, Bentwich Z, Cusini M, Bergamasco A, et al. Active anti-interferon-[alpha] immunization: A European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1 infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 358-70.
262. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni CE, Smolen JS, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
263. Zagury D, Le Buanec H, Bizzini B, Burny A, Lewis G, Gallo RC. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev 2003; 14: 123-37.
264. Suzuki H, Akama T, Okane M, Kono I, Matsui Y, Yamane K, et al. Interleukin-1-inhibitory IgG in sera from some patients with rheumatoid arthritis. Arthritis Rheum 1989; 32: 1528-38.
265. Svenson M, Poulsen LK, Fomsgaard A, Bendtzen K. IgG autoanti-bodies against interleukin 1alpha in sera of normal individuals. Scand J Immunol 1989; 29: 489-92.
266. Svenson M, Hansen MB, Bendtzen K. Distribution and characterization of autoantibodies to interleukin 1alpha in normal human sera. Scand J Immunol 1990; 32: 695-701.
267. Ross C, Hansen MBS, T, Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donnors. Clin Exp Immunol 1990; 82: 57-62.
268. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 1998; 91: 2054-61.
269. Bendtzen K, Hansen MB, Ross C, Svenson M. In: Peter J, Shoenfeld Y Ed, Autoantibodies. Amsterdam, Elsevier Science B.V. 1996, 209-16.
270. Bendtzen K, Svenson M, Jensson V, Hippe E. Autoantibodies to cytokines - friends or foes ? Immunol Today 1990; 11: 167-9.
271. Wildbaum G, Nahir MA, Karin N. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 2003; 19: 679-88.
272. Zagury D, Burny A, Gallo RC. Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines. PNAS 2001; 98: 8024-9.
273. Zagury D, Gallo RC. Anti-cytokine Ab immune therapy: Present status and perspectives. Drug Discov Today 2004; 9: 72-81.
274. Gorin PD, Johnson EM. Experimental autoimmune model of nerve growth factor deprivation: Effects on developing peripheral sympathetic and sensory neurons. PNAS 1979; 76: 5382-6.
275. Johnson EMJ, Gorin PD, Brandeis LD, Pearson J. Dorsal root ganglion neurons are destroyed by exposure in utero to maternal antibody to nerve growth factor. Science 1980; 210: 916-8.
276. Raaberg L, Nexo E, Jorgensen PE, Poulsen SS, Jakab M. Fetal effects of epidermal growth factor deficiency induced in rats by autoantibodies against epidermal growth factor. Pediatr Res 1995; 37: 175-81.
277. Capini CJ, Bertin-Maghit SM, Bessis N, Haumont PM, Bernier EM, Muel EG, et al. Active immunization against murine TNFalpha peptides in mice: Generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine 2004; 22: 3144-53.
278. Richard M, Grencis RK, Humphreys NE, Renauld J-C, Van Snick J. Anti-IL9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. PNAS 2000; 97: 767-72.
279. Zuany-Amorim CM, C, Dalum I, Jensen MR, Gautam A, Pay G, Mouritsen S, et al. Induction of TNF-alpha autoantibody production by AutoVac TNF106: A novel therapeutic approach for the treatment of allergic diseases. Int Arch Allergy Immunol 2004; 133: 154-63.
280. Uyttenhove C, Van Snick J. Development of an anti-IL-17A autovaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006; 36: 2868-74.
281. Delavallee L, Le Buanec H, Bessis N, Assier E, Denys A, Bizzini B, et al. Early and long-lasting protection from arthritis in TNF-alpha transgenic mice vaccinated against TNF-alpha. Ann Rheum Dis 2007: Epub ahead of print.
282. Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. PNAS 2007; 104: 2837-42.
283. Dalum I, Butler D, Jensen MR, Hindersson P, Steinaa LW, A. M, Grell SN, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 1999; 17: 666-9.
284. Waterston AMS, F, Andreakos EB, D. M, Feldmann MC, R. C. TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br J Cancer 2004; 90: 1279-84.
285. Waterston AM, Gumbrell L, Bratt T, Waller S, Gustav-Aspland J, Highley M, et al. Phase I study of TNFalpha autovaccine in patients with metastatic cancer. Cancer Immunol Immunother 2005; 54: 848-57.
286. Xue X, Feng G, Li M, Qin X, Wu S, Zhang C, et al. Amelioration of experimental autoimmune encephalomyelitis by BLyS autovaccine. Vaccine 2008; 26: 2873-81.
287. Röhn TA, Jennings GT, Hernandez M, Grest P, Beck M, Zou Y, et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2006; 36: 2857-67.
288. Tang D-c, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-4.
289. In: Paul WE Ed, Fundamental Immunology. Philadelphia, Lippincott Williams & Wilkins. 2003, 1331-2.
290. Youssef S, Wildbaum G, Karin N. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines. J Autoimmun 1999; 13: 21-9.
291. Wildbaum G, Youssef S, Karin N. A targeted DNA vaccine augments the natural immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis. J Clin Invest 2000; 106: 671-9.
292. Wildbaum G, Westermann J, Maor G, Karin N. A targeted DNA vaccine encoding Fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. J Clin Invest 2000; 106: 671-9.
293. Blank M, Krause I, Wildbaum G, Karin N, Shoenfeld Y. TNFalpha DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome. Lupus 2003; 12: 546-9.
294. Youssef S, Wildbaum G, Maor G, Lanir N, Gour-Lavie A, Grabie N, et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 1998; 161: 3870-9.
295. Youssef S, Maor G, Wildbaum G, Grabie N, Gour-Lavie A, Karin N. C-C chemokine-encoding DNA vaccines ehnance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest 2000; 106: 361-71.
296. Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N. Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol 2002; 169: 2685-93.
297. Garren H, Ruiz PJ, Watkins TA, Fontoura P, Nguyen L-V, Estline ER, et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 2001; 15: 15-22.
298. Schif-Zuck S, Wildbaum G, Karin N. Coadministration of plasmid DNA constructs encoding an encephalitogenic determinant and IL-10 elicits regulatory T cell-mediated protective immunity in the central nervous system. J Immunol 2006; 177: 8241-7.
299. Hertz M, Mahalingam S, Dalum I, Klysner S, Mattes J, Neisig A, et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol 2001; 167: 3792-9.
300. Shen Y, Chen J, Zhang X, Wu X, Xu Q. Human TNF-alpha gene vaccination prevents collagen-induced arthritis in mice. Int Immunopharmacol 2007; 7: 1140-9.
301. Tan GH, Su JMW, C. C, Huang FY, Wang H, Huang YH, Lin YY. A recombinant DNA plasmid encoding the human interleukin-5 breaks immunological tolerance and inhibits airway inflammation in a murine model of asthma. Int Arch Allergy Immunol 2008; 145: 313-23.
302. Karin N. Induction of protective therapy for autoimmune diseases by targeted DNA vaccines encoding pro-inflammatory cytokines and chemokines. Curr Opin Mol Ther 2004; 6: 27-33.
303. Bertin-Maghit SM, Capini CJ, Bessis N, Chomilier J, Muller S, Abbas A, et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine 2005; 23: 4228-35.
304. Hewer R, Meyer D. Peptide immunogens designed to enhance immune responses against human immunodeficiency virus (HIV) mutant strains: A plausible means of preventing viral persistence. J Theor Biol 2005; 233: 85-90.
305. Farris AD, Brown L, Reynolds P, Harley JB, James JA, Scofield RH, et al. Induction of autoimmunity by multivalent immunodominant and subdominant T cell determinants of La (SS-B). J Immunol 1999; 162: 3079-87.
306. Amexis G, Young NS. Multiple antigenic peptides as vaccine platform for the induction of humoral responses against Dengue-2 virus. Viral Immunol 2007; 20: 657-63.
307. Ma Y, HayGlass KT, Becker AB, Fan Y, Yang X, Basu S, et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 2007; 176: 439-45.
308. Torres D, Janot L, Quesniaux VFJ, Grivennikov SI, Maillet I, Sedgwick JD, et al. Membrane tumor necrosis factor confers partial protection to Listeria infection. Am J Pathol 2005; 167: 1677-87.
309. Cominelli F, Nast CC, Clark BD, Schindler R, Llerena R, Eysselein VE, et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990; 86: 972-80.
310. Henderson B, Thompson RC, Hardingham T, Lewthwaite J. Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine 1991; 3: 246-9.
311. Jacobs CA, Baker PE, Roux ER, Picha KS, Toivola B, Waugh S, et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 and suppressed by soluble IL-1 receptor. J Immunol 1991; 146: 2983-9.
312. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991; 30: 694- 700.
313. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. PNAS 1992; 89: 9784-8.
314. Geiger T, Towbin H, Cosenti-Vargas A, Zingel O, Arnold J, Rordorf C, et al. Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin Exp Rheumatol 1993; 11: 515-22.
315. Kim K, Li B, Winer J, Armanini M, Gillett N, Phillips H, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
316. Baker D, Butler D, Scallon B, O'Neill J, Turk J, Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24: 2040-8.
317. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995; 181: 381-96.
318. Neurath MF, Fuss B, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-90.
319. Coyle A, Le Gros G, Bertrand C, Tsuyuki S, Heusser C, Kopf M, et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol 1995; 13: 54-9.
320. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1996; 187: 461-8.
321. Renz H, Bradley K, Enssle K, Loader JE, Larsen GL, Gelfand EW. Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor;. Int Arch Allergy Immunol 1996; 109: 167-76.
322. Kojouharoff G, Hans W, Obermeier F, Männel DN, Andus T, Schölmerich AJ, et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997; 107: 353-8.
323. Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R. Treatment of ulcerative colitis in the cotton top tamarin using antibody to tumour necrosis factor alpha. Gut 1997; 40: 628-33.
324. Constantinescu CS, Wysocka M, Hilliard B, Ventura ES, Lavi E, Trinchieri G, et al. Antibodies against IL-12 prevent superantigeninduced and spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol 1998; 161: 5097-104.
325. Matthys P, Vermeire K, Mitera T, Heremans H, Huang S, Billiau A. Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-gamma receptor-deficient mice. Eur J Immunol 1998; 28: 2143-51.
326. Kumar RK, Herbert C, Webb DC, Li L, Foster PS. Effects of anticytokine therapy in a mouse model of chronic asthma. Am J Respir Crit Care Med 2004; 170: 1043-8.
327. Lubberts E, Koenders MI, Oppers-Walgreen B, Van den Bersselaar L, Coenen-de Roo CJJ, Joosten LAB, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction and bone erosion. Arthritis Rheum 2004; 50: 650-9.
328. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, et al. Therapeutic efficacy of IL-17 neutralization murine experimental autoimmune encephalomyelitis. Cell Immunol 2005; 237: 123-30.
329. Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan TK, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006; 116: 1317-26.
330. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie B, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006; 203: 2473-93.
331. Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 2007; 9: R96.